Drug intelligence / Profile preview

deselsulfavirine

Development stage: Phase 3
Lead developer: Viriom
Modality: Small Molecules
Administration: Intramuscular

Overview

Deselsulfavirine (VM-1500A) is a small molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) and the active metabolite of the prodrug elsulfavirine. Developed by Viriom Inc., it is being evaluated for the treatment and prevention (PrEP) of HIV-1 infection. Deselsulfavirine works by binding to an allosteric site on the HIV-1 reverse transcriptase enzyme, which inhibits the enzyme's activity and prevents the conversion of viral RNA into DNA, thereby blocking viral replication. The drug is specifically being developed as a long-acting injectable formulation to provide a more convenient dosing schedule and improve adherence compared to daily oral regimens.

Other names: deselsulfavirine long-acting injectable

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on deselsulfavirine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deselsulfavirine.

Explore the full profile